POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

被引：0

作者：

Vachhani, Pankit ^{[1
]}

Rampal, Raajit ^{[2
]}

Bradley, Terrence ^{[3
]}

Harrison, Claire ^{[4
]}

Jain, Tania ^{[5
]}

Kuykendall, Andrew T. ^{[6
]}

Palandri, Francesca ^{[7
]}

Mascarenhas, John O. ^{[8
]}

Al-Ali, Haifa Kathrin ^{[9
]}

Passamonti, Francesco ^{[10
,11
]}

Nekhymchuk, Anna ^{[12
]}

Foss, Hilarie

Rothbaum, Wayne ^{[12
]}

Verstovsek, Srdan ^{[12
]}

Heidel, Florian ^{[13
]}

机构：

[1] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Guys & St Thomas NHS Fdn Trust, London, England

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Univ S Florida, Moffitt Canc Ctr, Tampa, FL USA

[7] IRCCS Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Ist Ematol Serygnoli, Bologna, Italy

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[9] Univ Hosp Halle, Halle, Saale, Germany

[10] Fdn IRCCS CaGranda Osped Maggiore Policlin Milano, Dept Pathophysiol & Transplantat, Milan, Italy

[11] Univ Milan, Dipartimento Oncol & Oncoematol, Milan, Italy

[12] Kartos Therapeut Inc, Redwood City, CA USA

[13] Hannover Med Sch, Hannover, Germany

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200966

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：18083 / 18084

页数：2

共 50 条

[1] A randomized, double-blind, placebo-controlled phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosis who have suboptimal response to ruxolitinib
Yacoub, Abdulraheem
Stouffs, Michael
Zhou, Feng
Assad, Albert
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 112 - 113
[2] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib.
Yacoub, Abdulraheem
Stouffs, Michael
Zhou, Feng
Assad, Albert
CANCER RESEARCH, 2021, 81 (13)
[3] ReTHINK: A randomized, double-blind, placebo controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
Passamonti, Francesco
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Reiter, Andreas
Bharathy, Savita
Iommazzo, Dana
Stalbovskaya, Viktoriya
Gopalakrishna, Prashanth
Mesa, Ruben A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
Yacoub, Abdulraheem
Erickson-Viitanen, Sue
Zhou, Feng
Assad, Albert
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 115 - 116
[5] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
Yacoub, Abdulraheem
Erickson-Viitanen, Susan
Zhou, Feng
Assad, Albert
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naive Myelofibrosis.
Yacoub, Abdulraheem
Erickson-Viitanen, Sue
Zhou, Feng
Assad, Albert
CANCER RESEARCH, 2021, 81 (13)
[7] Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
Pemmaraju, Naveen
Mead, Adam J.
Somervaille, Tim C. P.
McCloskey, James K.
Palandri, Francesca
Koschmieder, Steffen
Lavie, David
Leber, Brian
Yeh, Su-Peng
Gomez-Casares, Maria Teresa
Ammatuna, Emanuele
Shin, Ho-Jin
Kirito, Keita
Jourdan, Eric
Devos, Timothy
Chuah, Hun S.
Radinoff, Atanas
Bogdanovic, Andrija
Moskal, Rastislav
Jiang, Qi
Chopra, Avijeet S.
Papadopoulos, Elektra
Potluri, Jalaja
Passamonti, Francesco
BLOOD, 2023, 142
[8] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Mertz, Jennifer A.
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Senderowicz, Adrian
Humphrey, Jeffrey S.
Verstovsek, Srdan
BLOOD, 2020, 136
[9] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
Passamonti, F.
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Vannucchi, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
HAEMATOLOGICA, 2021, 106 (10) : 81 - 82
[10] BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naive or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Harrison, Claire
Bose, Prithviraj
Rampal, Raajit K.
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Hobbs, Gabriela
Talpaz, Moshe
Vannucchi, Alessandro
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Hoffman, Ron
Salama, Mohamed E.
Chen, Dong
Taverna, Pietro
Chang, Alex
Colak, Gozde
Klein, Sandra
Gupta, Vikas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S335 - S336

← 1 2 3 4 5 →